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CardiOvaScular Mechanisms In Covid‑19:
methodology of a prospective observational
multimodality imaging study (COSMIC‑19 study)
Shirjel R. Alam1†, Anoop S. V. Shah2*† , Kevin O. Ombati3, Edward Nganga3, Samuel Gitau3, Khalid Makhdomi3,
Michael H. Chung4 and Sudhir Vinayak3

Abstract
Background: 8–28% of patients infected with COVID-19 have evidence of cardiac injury, and this is associated with
an adverse prognosis. The cardiovascular mechanisms of injury are poorly understood and speculative. We aim to use
multimodality cardiac imaging including cardiac magnetic resonance (CMR) imaging, computed tomography coronary angiography (CTCA) and positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-d-glucose integrated
with computed tomography (18F-FDG-PET/CT) to identify the cardiac pathophysiological mechanisms related to
COVID-19 infections.
Methods: This is a single-centre exploratory observational study aiming to recruit 50 patients with COVID-19 infection who will undergo cardiac biomarker sampling. Of these, 30 patients will undergo combined CTCA and 18F-FDGPET/CT, followed by CMR. Prevalence of obstructive and non-obstructive atherosclerotic coronary disease will be
assessed using CTCA. CMR will be used to identify and characterise myocardial disease including presence of cardiac
dysfunction, myocardial fibrosis, myocardial oedema and myocardial infarction. 18F-FDG-PET/CT will identify vascular
and cardiac inflammation. Primary endpoint will be the presence of cardiovascular pathology and the association
with troponin levels.
Discussion: The results of the study will identify the presence and modality of cardiac injury associated COVID-19
infection, and the utility of multi-modality imaging in diagnosing such injury. This will further inform clinical decision
making during the pandemic.
Trial Registration: This study has been retrospectively registered at the ISRCTN registry (ID ISRCTN12154994) on 14th
August 2020. Accessible at https://www.isrctn.com/ISRCTN12154994
Keywords: COVID-19, CMR, FDG, 18F-FDG-PET/CT, CTCA, Cardiovascular, Troponin, Cardiac injury, Imaging
Background
The number of people diagnosed with the coronavirus
disease 2019 (COVID-19) [1] has surpassed 150 million
worldwide claiming over 3.2 million deaths [2]. Patients
*Correspondence: anoop.shah@lshtm.ac.uk
†
Shirjel R. Alam and Anoop S.V. Shah have contributed equally to this
work
2
London School of Hygiene and Tropical Medicine, London, UK
Full list of author information is available at the end of the article

with underlying cardiovascular comorbidity are more
severely affected, with 8–28% of patients showing evidence of heart injury [3, 4]. These patients exhibit a substantially higher death rate [5]. The odds of in-hospital
death were 80-fold higher in patients with elevated cardiac troponin concentrations [6].
At present, the cardiovascular pathology of injury in
COVID-19 patients remain poorly understood, with the
underlying mechanism being speculative [6, 7]. To date,
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cardiac manifestations of COVID-19 infection have been
limited to case reports and series or in patient populations who have already survived COVID-19 with imaging
evaluating medium-term cardiac sequelea of COVID-19
[8–10].
Using cardiac magnetic resonance (CMR) imaging [11–
13], computed tomography coronary angiogram (CTCA)
[14] and positron emission tomography with 2-deoxy2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG-PET/CT) [15] during acute
COVID-19 infection, we intend to investigate structural
and functional changes of the myocardium and arterial
vasculature, including evidence of inflammation, fibrosis
and prevalence of underlying coronary atherosclerosis.
Our principal aims are to identify the cardiac pathophysiological mechanisms related to COVID-19 infection
that would influence care and clinical outcomes and provide insight into potential therapeutic targets.

Methods/design
This is a single-centre exploratory observational study
involving participants diagnosed with COVID-19 receiving care at the Aga Khan University Hospital in Nairobi, Kenya. We aim to recruit around 50 patients with
COVID-19 infection with 20 to 30 patients undergoing
cardiac imaging. If feasible we will aim to image 15–20
with plasma troponin levels, using a high-sensitivity
assay, above the 99th centile upper reference limit (URL)
and 5–10 patients with troponin levels within the normal
reference range. We will additionally identify a control
population of individuals where COVID-19 is suspected
but excluded following testing. We will attempt to match
controls by age and sex to the COVID-19 positive population. All patients not requiring non-invasive and invasive ventilation will be eligible for recruitment.
Selection criteria

Inclusion criteria for patients diagnosed with COVID19 include those over the age of 18 years, testing positive
on PCR testing and ideally within 2 weeks of a positive
test. Patients will be excluded based on the following
conditions: (1) prior diagnosis of myocardial infarction,
coronary revascularisation or cardiac surgery; (2) requiring invasive or non-invasive ventilation; (3) inability to
undergo CT or CMR scanning; (4) severe renal failure
(estimated glomerular filtration rate < 30 mL/min); (5)
Major allergy to iodinated contrast media/gadolinium;
(6) pregnancy or breast feeding; (7) inability to give
informed consent; (8) contraindication to imaging example metal fragments in the eye. Similarly exclusion criteria will apply to patients over the age of 18 years chosen
as controls and testing negative for COVID-19.
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We will also explore stratification by clinical parameters of COVID-19 severity. As such we will also provide
baseline characteritics and imaging parameters by clinical requirement of oxygen supplementation.
Protection of staff and patients from COVID‑19 infection

All staff involved in scanning patients will wear personal
protective equipment (PPE) in line with hospital policy,
and follow protocols created by the study team including physicians from the infectious diseases team. Patients
will be scanned last on the list followed by a deep clean
to the scanning area to prevent nosocomial cross infection. Routine clinical scans will be prioritised over
research scans. No aerosol producing procedures will be
performed.
Image acquisition

At initial recruitment, patients will undergo blood sampling for high-sensitivity cardiac troponin, N-terminal
pro B-type natriuretic peptide and high-sensitivity C
Reactive protein. A subset of patients will be selected
for multimodality cardiovascular imaging. These participants will undergo two visits for a combined CTCA
and 18F-FDG-PET/CT as soon as possible, followed by
a CMR on another visit. All CTCA and 18F-FDG-PET/
CT will be performed within 2 weeks of presentation to
maximise sensitivity of the scan. All efforts will be made
to ensure CMR scans are also performed within 2 week,
however scanning beyond this point will be performed
if it is logistically impossible to perform the scan within
this window.
Computed tomography coronary angiogram

CTCA scanning will be ECG-gated and performed
in diastole during a single breath hold with prospective electrocardiographic gating, detector collimation
64 × 0.625 mm, tube voltage 120 kV and window of
acquisition 70–90% (or wider if necessary due to heart
rate). Tube current will vary depending on BMI using a
pre-specified manufacturer protocol. After the acquisition of scout images, CTCA will be performed with
iodinated contrast (Ultravist 370 mg/mL) in a biphasic
injection protocol. Image acquisition will be triggered
by contrast enhancement of 100 HU in the ascending aorta. In order to optimise the quality of the CTCA
scan images, heart rate control will be pharmacologically
achieved if appropriate, and in addition sublingual glyceryl trinitrate will be administered.
18F‑FDG‑PET/CT

Participants will undergo 18F-FDG-PET/CT imaging after high-fat, low-carbohydrate meal for 24 h with
18 h fast to reduce physiologic myocardial FDG uptake
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[15, 16]. The PET imaging will be performed 60–90 min
after administration of 10–15 mCi of 18F-FDG using a
GE Discovery MI series PET/CT (64 slice) scanner. The
carotid arteries will be the superior aspect of imaging,
and the entire thoracic aorta will be covered using 3 min
different bed positions with additional dedicated 10 min
cardiac acquisition. CT images will be obtained immediately after PET scan acquisition and the images co-registered following re-construction.
Cardiac magnetic resonance

Standard CMR images will be acquired as previous [17–
19]. In brief, standard pilot images and cardiac views will
be obtained using breath-held acquisitions. Sequences
will be as follows: (1) HASTE/White blood axial; (2)
cines 2, 3 and 4 chamber; (3) T1 map short axis basal and
mid-ventricular short axis slices, with additional long
axis images if possible; (4) T2 map short axis basal and
mid-ventricular short axis slices, with additional long
axis images if possible; (5) post gadolinium contrast PSIR
short axis cine stack, 2, 3 and 4 chamber; (6) post contrast T1 map short axis basal and mid-ventricular short
axis slices; (7) aortic flow map.
Gadolinium-based contrast agent will be intravenously
administered. Myocardial infarction and fibrosis will be
identified by the presence of hyperenhancement in the
myocardium in late enhancement images, acquired using
a T1-inversion sequence with inversion time optimised
on a patient-by-patient basis [20]. Multiple slices will be
acquired in the short axis view with inversion time further optimised for each slice. Two- and 4-chamber late
enhancement views will also be acquired to verify presence or absence of late enhancement. Late enhancement
images will be acquired approximately 5–12 min after
gadolinium infusion. T1 characteristics, extra cellular volume as well as the presence of cardiac oedema by
T2-maps will be assessed [11, 13, 21].
Image analysis

All scans will be anonymised, with analysts blinded to all
blood results and other scanning modalities. The cardiac
MRIs will be analysed in Manchester (UK), PET scans
in Bristol (UK) and CTCAs in Edinburgh (UK). There
will be no discussion regarding scans between the centres. When a second opinion is needed, it will be sought
from an independent radiologist in Nairobi (Kenya). All
analysis will be performed by expert cardiologists trained
in the relevant cardiac imaging modalities. The second opinion, when sought, will be performed by expert
cardiothoracic radiologists.
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Computed tomography coronary angiography

The presence of coronary artery disease in each major
coronary artery, and the main side branches will be documented based on degree of stenosis. In addition presence of coronary calcification, other cardiac or vascular
pathology, pericardial pathology and aortic/main pulmonary artery diameter will be recorded.
18F‑FDG‑PET/CT

Arterial inflammation: Aortic inflammation will be
assessed as previous [15, 22]. In brief CT and PET scan
images will be co-registered automatically. The aorta will
be divided into axial slices, and the tracer standardised
uptake value (SUV) measured from a point distal to the
origin of coronary vessels to avoid myocardial spill-over.
Regions of interest will be drawn around the aorta in the
axial position, repeated along the length of the aorta. A
mean arterial SUV will be derived from the average of the
maximum SUV values in serial axial measurements. Similarly the average of SUV measurements from the venous
pool will derive the mean venous background SUV. The
target-to-background (TBR) ratio will then be calculated
by dividing the mean arterial SUV by the mean venous
SUV.
Myocardial inflammation: Myocardial uptake will be
assessed as previous [23–27]. In brief CT and PET scan
images will be co-registered. Analysis will be performed
on short-axis cardiac slices for later comparison with
CMR using 17 segment model [28]. Liver SUV uptake
will be measured by drawing a hepatic region of interest.
Uptake in the heart as a whole will be scored according to
a visual scale to assess cardiac suppression of FGD uptake
(ie adequate fasting/dietary preparation).
Visual assessment of myocarditis:
A visual assessment of FDG uptake (on diagnostic scans) that signifies myocarditis will be categorised:
None—1, focal on diffuse—2, Focal—3, Diffuse—4.
Objective assessment of myocarditis:
Each segment of the 17 segment model, will be assessed
for myocardial uptake visually. In addition, regions of
interest within each myocardial segment of the 17-segment model will be drawn avoiding the blood pool and
liver.
A mean cardiac SUV will be derived from the average
of the maximum SUV values in serial short axis measurements (Sum of each segment /17).
Assessment of each segment of the 17 segment model
will be performed in 3 different ways as follows.
1. Raw SUV uptake compared to blood pool uptake will
be calculated for each segment, and categorised.

Alam et al. BMC Cardiovasc Disord

(2021) 21:234

2. TBR (target-to-background-ratio) will be calculated
by dividing each cardiac segment SUV by the mean
blood pool SUV
3. Each segment indexed to the mean blood pool will
also be categorised (0—uptake < mean blood pool
uptake),1—uptake = mean blood pool uptake,2—
uptake > mean blood pool uptake but < liver uptake,
3—(uptake > liver uptake)
Cardiac magnetic resonance imaging

Ejection fraction, regional wall motion abnormalities,
myocardial fibrosis, oedema and presence of infarction
will be determined as previously described [11, 13, 29].
Briefly, epicardial and endocardial contours will be drawn
around diastolic phase cines, and endocardial contours
around systolic phase cines to calculate cardiac volumes
and myocardial mass. The myocardium will be separated
into 16 segments of the American Heart Association
17-segment model excluding the apex [28]. T1 values,T2
values, extra cellular volume and the presence of late
gadolinium enhancement will be generated for each segment using dedicated software. T1 values will indicate
fibrosis, T2 values oedema and gadolinium enhancement
the presence of infarction as well as fibrosis depending on
distribution [11, 13, 20].

Primary objectives
We have four primary objectives:
• Identify the proportion of patients with biochemical
evidence of myocardial injury or strain with the presence of elevated cardiac troponin.
• Identify significant atherosclerotic disease potentially
causing cardiac injury with the presence of obstructive coronary artery disease on CTCA (> 50%).
• Identify myocardial disease using CMR by determining ejection fraction, presence of myocardial
infarction (sub-endocarditis gadolinium enhancement), myocarditis (mid-wall/epicardial gadolinium
enhancement) or myocardial oedema (elevated T1
values and T2 values)
• Identify vascular inflammation by 18F-FDG-PET/CT
by quantifying increased FDG uptake in aorta. Determining the presence of different patterns of FDG
uptake in myocardium will be a secondary exploratory outcome.

Sample size calculation and statistics
Based on published literature we based our sample size
calculation on the assumption that 1 in 4 of hospitalised
COVID-19 patients will have elevated cardiac troponin
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[3]. In sample size calculations, we estimated that with
50 patients, we would be able to estimate the confidence
interval for a prevalence of 25% with lower and upper
intervals of 14.1% and 37.4% respectively, and that we
would have 80% power for an alpha of 0·05 to test the
null hypothesis that the prevalence was < 10%. This is an
exploratory observational cross-sectional study to investigate the potential cardiac mechanisms in patients with
COVID-19. As such we have not performed any formal
power calculations based on imaging parameters.
Baseline clinical and imaging data will will be expressed
as the mean ± standard deviation (SD) for parametric
data and median (interquatile range) for non-parametric
data. Categorical data will be presented as proportions.
We will conduct hypothesis testing based on imaging
parameters comparing (a) controls and patients and (b)
within patients, those stratified by troponin concentrations. For within patient analysis we will attempt to
compare individuals stratified above and below the 99th
centile for cardiac troponin concentration. If the number
of patients above the 99th centile for cardiac troponin are
small, we will group patients by equal strata of cardiac
troponin value. We will also explore stratification by clinical parameters of COVID-19 severity. As such we will
provide also provide baseline characteritics and imaging
parameters by clinical requirement of oxygen supplementation. P value of less than 0.05 will indicate statistical
significance.

Discussion
In order to understand cardiac complications secondary
to COVID-19, this study aims to utilise multimodality
cardiac imaging to identify any morphological and functional cardiovascular changes associated with infection.
To date, whilst data has shown that myocardial injury is
prevalent in patients with COVID-19, cardiac imaging
has either been limited to case reports and small case
series, performed after recovery using single modalities
or using study designs highly susceptible to selection/
reporting [8–10].
To our knowledge, our study represents the first multimodality cardiac imaging study, with each technique
attempting to elucidate specific pathophysiological processes. CTCA will examine the presence of coronary disease associated directly or indirectly with elevated cardiac
troponin concentrations, and its absence would imply
Type 2 myocardial infarction in the correct context. CMR
will evaluate cardiac function and dysfunction including
structural evidence of heart failure resulting from either
ischaemic or non-ischaemic cardiomyopathy (e.g. stress
cardiomyopathy). It will also identify myocardial infarction or fibrosis caused by myocarditis. 18F-FDG-PET/CT
can assess for myocardial and vascular inflammation that
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would delineate if myocardial oedema (seen on CMR) is
caused by direct cardiac injury or as part of a generalised
inflammatory process.
Identification of each pathophysiological process will
inform future studies in evaluating optimal choices of
therapeutic agents; (1) anti-platelet and anti-coagulation agents for atherosclerotic disease or thrombotic
occlusions; (2) Blood pressure and oxygen support in
the presence of type 2 myocardial infarction; (3) antiviral or anti-inflammatory strategies for a primary
myocarditic processes; (4) early and long term cardioprotective therapy for myocardial dysfunction.
There are several limitations and considerations that
need to be taken into account with regards to our study
design. First, given the imaging strategy undertaken,
patients must be fit enough for example to breathhold.
As such our study primarily aims to recruit COVID-19
cases who are not requiring invasive or non-invasive
ventilation. Our findings may therefore not be generalisable to severe cases of COVID-19. Second, recent
evidence has shown the role of anti inflammatories
in managing patients with COVID-19. These drugs
are likely to modulate the degree of inflammatory signal seen in the myocardium and arterial tree and may
underestimate the true pathophysiological effect of
the disease on the heart. Thirdly, manual selection or
regions of interest during scan analysis is liable to error.
This may be compounded by diminished scan quality
due to infected patients being short of breath or tachycardic. Finally, the observational trial aims to recruit
a relatively small number of patients, and clinical outcomes will not be evaluated. However there is a lack of
data and well designed studies investigating COVID-19
cardiovascular injury, and the study should provide valuable insights.
Abbreviations
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